Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immuneering (IMRX) Net Income (2020 - 2026)

Immuneering's Net Income history spans 7 years, with the latest figure at -$14.0 million for Q1 2026.

  • On a quarterly basis, Net Income rose 7.12% to -$14.0 million in Q1 2026 year-over-year; TTM through Mar 2026 was -$55.3 million, a 10.87% increase, with the full-year FY2025 number at -$56.3 million, up 8.36% from a year prior.
  • Net Income came in at -$14.0 million for Q1 2026, down from -$11.9 million in the prior quarter.
  • The five-year high for Net Income was -$11.5 million in Q2 2022, with the low at -$18.1 million in Q4 2024.
  • Historically, Net Income has averaged -$14.0 million across 5 years, with a median of -$14.0 million in 2026.
  • Biggest five-year swings in Net Income: crashed 105.36% in 2022 and later surged 34.46% in 2025.
  • Year by year, Net Income stood at -$13.5 million in 2022, then decreased by 15.44% to -$15.5 million in 2023, then dropped by 16.69% to -$18.1 million in 2024, then surged by 34.46% to -$11.9 million in 2025, then decreased by 17.52% to -$14.0 million in 2026.
  • Business Quant data shows Net Income for IMRX at -$14.0 million in Q1 2026, -$11.9 million in Q4 2025, and -$15.0 million in Q3 2025.